HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.2%

Neg 0% Neu 91.2% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.